December 8, 2011

NanoBio to Collaborate in Research Effort for Respiratory Syncytial Virus Vaccine with Merck

August 24, 2011

NanoBio's Intranasal RSV Vaccine Induces Robust Immunity in Animals

August 3, 2011

NanoBio Secures Novel Antigen Source for its Intranasal RSV Vaccine

July 20, 2011

NanoBio Announces Publication of Study Results for Intranasal Nanoemulsion-Adjuvanted Vaccine

June 21, 2011

NanoBio Announces First Patients Vaccinated in Phase 1b Intranasal Influenza Vaccine Study

June 14, 2011

George Arida Named to NanoBio Board of Directors

May 24, 2011

NanoBio Appoints Peter Ulrich to Board of Directors

May 11, 2011

NanoBio and GSK Commence Phase 3 Studies of Nanoemulsion-based OTC Treatment for Cold Sores

April 20, 2011

NanoBio Announces Development of Nasal Vaccine for the Prevention of Urinary Tract Infections in Collaboration with the University of Michigan

November 30, 2010

NanoBio Receives $6 Million to Develop an Intranasal Vaccine for Respiratory Syncytial Virus

November 17, 2010

Dr. Ali Fattom Joins NanoBio to Lead the Company’s Vaccine Research Efforts

October 25, 2010

NanoBio® CEO to Present at the 6th Annual Grand Challenges in Global Health Meeting

October 12, 2010

NanoBio® and the University of Michigan Awarded $1.5M Department of Defense
Grant to Study Topical Anti-infective Treatment for Combat Related Injuries

September 29, 2010

NanoBio® Awarded Licensing Executive Society’s “Deal of Distinction”
for Licensing Agreement with GlaxoSmithKline

September 10,2010

NanoBio® to Present Clinical Data on its Nanoemulsion Adjuvanted Intranasal Flu Vaccine and Novel Anti-Acne Treatment at ICAAC 2010

August 3, 2010

NanoBio Awarded New Patent Covering its Nanoemulsion-based Anti-infective Product Candidate for the Treatment of Cold Sores

April 19, 2010

NanoBio Launches Development Program for a Therapeutic Intranasal Vaccine for the Treatment of Hepatitis B

February 2, 2010

NanoBio Awarded Key Patent Covering Vaccine and Anti-infective Product Platforms

December 16, 2009

GSK and NanoBio Announce Licensing Agreement

December 7, 2009

NanoBio to Present Data on its Novel Nanoemulsion-based Vaccine Adjuvant Platform at the World Influenza Congress

December 2, 2009

Novel Intranasal Nanoemulsion Vaccine Adjuvant also Effective by Subcutaneous and Intramuscular Injection

October 15, 2009

NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found in Cystic Fibrosis Patients

October 13, 2009

NanoBio and the University of Michigan to Receive $9.3M from the NIH for Nanoemulsion-Based Vaccine Development

September 14, 2009

NanoBio Presents Key Data on the Use of Nanoemulsions to Treat Burn Wound Infections

September 8, 2009

NanoBio's Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza

August 17, 2009

NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based
Vaccine Adjuvant Platform at the Immunotherapeutics & Vaccine Summit

July 29, 2009

NanoBio to Announce Key Preclinical Data on Nanoemulsions for the Treatment of Acne at American Academy of Dermatology Summer Meeting

July 8, 2009

NanoBio Announces Closing of $22 Million Series B Financing Round Funds will Support Clinical Trials and Ongoing Operations Through Early 2011

May 6, 2009

NanoBio to Announce Key Preclinical Data on Topical Anti-infective Lotions at Society of Investigative Dermatology Meeting

April 23, 2009

NanoBio to Announce Key Immune Response Data for Influenza at NFID Conference

April 20, 2009

NanoBio Initiates FDA Approved Clinical Trial for Adjuvanted Intranasal Influenza Vaccine

March 2, 2009

NanoBio to Announce Key clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009

January 29, 2009

Nanoemulsion Kills Highly Resistant Bacteria Found in Patients with Cystic Fibrosis

November 13, 2008

NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists

October 28, 2008

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

October 27, 2008

NanoBio Demonstrates New Topical Approach to Treating Nail Fungus that Circumvents Problems of Current Therapy

October 27, 2008

Nanoemulsion-based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity using Significantly Less Antigen

October 21, 2008

NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008

August 13, 2008

Nasal Hepatitis B Vaccine Elicits Robust Immunity with a Single Dose; Confers a Major Advantage over Traditional Vaccines

July 8, 2008

Daniel B. Dubin, MD Joins NanoBio Corporation’s Board of Directors

June 24, 2008

FierceBiotech Names NanoBio Corporation as One of the “Fierce 15" Biotech Companies of 2008

May 29, 2008

David M. Stout Joins NanoBio Corporation's Board of Directors

March 20, 2008

NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis

March 17, 2008

NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis

March 11, 2008

NanoBio Founder Named 2008 Distinguished University Innovator

March 06, 2008

NanoBio Corporation Completes $30 Million Funding by Meeting Key Development Milestones

February 26, 2008

Nasal Vaccine for Smallpox Confers High Levels of Immunity without Safety Risks

February 1, 2008

NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008

January 30, 2008

New Patent Awarded for Vaccine Adjuvant Technology that Elicits Robust Immunity

January 15, 2008

Stephen Gracon, D.V.M., Joins the NanoBio Team as VP of Regulatory Affairs

October 30, 2007

Joyce Sutcliffe, PhD, Joins the NanoBio Team as Vice President of Research

October 5, 2007

NanoBio Wins 2007 Michigan Innovation Award

September 25, 2007

NanoBio Expands Drug Development Team for its Anti-Infective Products

September 19, 2007

New Topical Therapy Safely Treats Serious Skin Infections without Systemic Side Effects

August 16, 2007

Easy-to-use nasal anthrax vaccine offers strong protection in animal studies

July 17, 2007

Jerald C. Sadoff, MD Joins NanoBio Scientific Advisory Board

July 10, 2007

NanoBio® Corporation Receives $2.4M Award From Michigan's 21st Century Jobs Fund

May 22, 2007

NanoBio® Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis

April 3, 2007

NanoBio Corporation Initiates Phase 2 Clinical Trial for the treatment of Onychomycosis

February 15, 2007

NanoBio Corporation Initiates Phase 2b Clinical Trial for Herpes Labialis Treatment

October 11, 2006

NanoBio Corporation Announces Appointment of Dr. Ronald Cresswell to Board of Directors

September 27, 2006

Dr. Robert C. Moellering, Jr. Joins NanoBio Corporation's Board of Directors

August 7, 2006

NanoBio Secures $30 Million Private Equity Financing

February 9, 2006

David Peralta Joins NanoBio as CFO

July 11, 2005

$6.3M Gates Foundation Grant Secured for Development of a NanoStat™ Based Mucosal Vaccine

June 17, 2004

Jay Birnbaum, Ph.D., Joins Science Advisory Board

January 29, 2004

Three New Patents Awarded

December 16, 2003

Dept. of Defense Awards NanoBio $3.2 Million Contract